Granulocyte transfusion

Current Opinion in Hematology

Volumn 13, Issue 1, 2006, Pages 45-49

  Atallah, Ehab ^a   Schiffer, Charles A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Granulocytes; Neutropenia; Transfusion

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOIMMUNIZATION; BIOCOMPATIBILITY; BLOOD TRANSFUSION REACTION; BONE PAIN; BRONCHOSPASM; GRANULOCYTE TRANSFUSION; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOXEMIA; INSOMNIA; LYMPHOCYTOTOXICITY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; GRANULOCYTE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; INFECTION; LEUKOCYTE TRANSFUSION; TRANSPLANTATION;

ABO BLOOD-GROUP SYSTEM; BLOOD DONORS; GRANULOCYTES; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; INFECTION; LEUKOCYTE TRANSFUSION; NEUTROPENIA;

EID: 33644848150     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000190114.38650.b2     Document Type: Review

References (38)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340.
2. Freireich EJ, Levin RH, Whang J, et al. The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann N Y Acad Sci 1964; 113:1081-1089.
3. Schiffer CA. Granulocyte transfusion therapy. Cancer Treat Rep 1983; 67:113-119.
4. Graw RG Jr, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to Gram-negative bacteria. N Engl J Med 1972; 287:367-371.
5. Higby DJ, Yates JW, Henderson ES, Holland JF. Filtration leukapheresis for granulocyte transfusion therapy: clinical and laboratory studies. N Engl J Med 1975; 292:761-766.
6. Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977; 63:548-555.
7. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977; 296:706-711.
8. Herzig RH, Herzig GP, Graw RG Jr, et al. Successful granulocyte transfusion therapy for Gram-negative septicemia: a prospectively randomized controlled study. N Engl J Med 1977; 296:701-705.
9. Fortuny IE, Bloomfield CD, Hadlock DC, et al. Granulocyte transfusion: a controlled study in patients with acute nonlymphocytic leukemia. Transfusion 1975; 15:548-558.
10. Winston DJ, Ho WG, Gale RP. Therapeutic granulocyte transfusions for documented infections: a controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 1982; 97:509-515.
11. Appelbaum FR, Trapani RJ, Graw RG Jr. Consequences of prior alloimmunization during granulocyte transfusion. Transfusion 1977; 17:460-464.
12. Dahlke MB, Keashen MA, Alavi JB, et al. Response to granulocyte transfusions in the alloimmunized patient. Transfusion 1980; 20:555-558.
13. Dutcher JP, Schiffer CA, Johnston GS, et al. Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. Blood 1983; 62:354-360.
14. McCullough J, Weiblen BJ, Clay ME, Forstrom L. Effect of leukocyte antibodies on the fate in vivo of indium-111-labeled granulocytes. Blood 1981; 58:164-170.
15. Ungerleider RS, Appelbaum FR, Trapani RJ, Deisseroth AB. Lack of predictive value of antileukocyte antibody screening in granulocyte transfusion therapy. Transfusion 1979; 19:90-94.
16. Adkins DR, Goodnough LT, Shenoy S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 2000; 95:3605-3612.
17. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:1883-1888.
18. Schiffer CA. Granulocyte transfusion therapy. Curr Opin Hematol 1999; 6: 3-7.
19. Schiffer CA, Aisner J, Dutcher JP, Wiernik PH. Sustained post-transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J Hematol 1983; 15:65-74.
20. Joos K, Herzog R, Einsele H, et al. Characterization and functional analysis of granulocyte concentrates collected from donors after repeated G-CSF stimulation. Transfusion 2002; 42:603-611.
21. Cesaro S, Chinello P, De Silvestro G, et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer 2003; 11:101-106.
22. Illerhaus G, Wirth K, Dwenger A, et al. Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Ann Hematol 2002; 81:273-281.
23. Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia 2001; 15:203-207.
24. Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 11 June [Epub ahead of print]. Most recent study showing the benefit for granulocyte transfusions in this era with the use of advanced antimicrobials.
25. Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106: 689-696.
26. Price TH. Granulocyte transfusion in the G-CSF era. Int J Hematol 2002; 76 (Suppl 2):77-80.
27. Hubel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002; 42:1414-1421.
28. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 1997; 12: 74-81.
29. Schiffer CA, Aisner J, Daly PA, et al. Alloimmunization following prophylactic granulocyte transfusion. Blood 1979; 54:766-774.
30. Kerr JP, Liakopolou E, Brown J, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003; 123:114-118.
31. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943-948.
32. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
33. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11:1621-1630.
34. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859-2865. A recent large retrospective study on the use of granulocyte transfusion in leukemic patients which showed benefit in high-risk patients with systemic candidal infection.
35. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304:1185-1189.
36. Dutcher JP, Kendall J, Norris D, et al. Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol 1989; 31:102-108.
37. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001; 41:1464-1468.
38. Vij R, DiPersio JF, Venkatraman P, et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101:2067-2069.